Notice of Intent to Publish a Funding Opportunity Announcement for Facilitating Preclinical and Early Phase Human Studies for New Therapeutics (UG3/UH3 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for facilitating preclinical and early phase human studies for new therapeutics, specifically targeting aging-related conditions. This initiative aims to advance T1 translational aging research, focusing on therapeutics that progress from preclinical stages to first-in-human trials, including treatments for conditions such as sarcopenia and heart failure with preserved ejection fraction (HFpEF). The funding opportunity, categorized under health-related activities, will utilize the UG3/UH3 cooperative agreement mechanism, with an estimated total program funding of $2.5 million. The NOFO is expected to be published in summer 2024, with applications due in fall 2024, and the anticipated award date is July 1, 2025. Interested applicants are encouraged to prepare their research plans and identify potential collaborators in advance.